Literature DB >> 26378286

Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae.

Stefan Riedel1, James E Ross2, David J Farrell2, Robert K Flamm2, Ronald N Jones3.   

Abstract

This solithromycin quality control study was performed to establish quality control (QC) ranges for the N. gonorrhoeae ATCC 49226 control strain for MIC agar dilution testing (AD) and zones by disk diffusion testing (DD). The following ranges were established: AD, 0.03 to 0.25 μg/ml, and DD, 33 to 43 mm. In January 2015, the CLSI Subcommittee on Antimicrobial Susceptibility Testing approved these ranges, which will be important when evaluating solithromycin against clinical isolates of N. gonorrhoeae.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26378286      PMCID: PMC4652126          DOI: 10.1128/JCM.02250-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  6 in total

1.  Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing.

Authors:  John Turnidge; Gerry Bordash
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

2.  CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.

Authors:  Shannon D Putnam; Mariana Castanheira; Gary J Moet; David J Farrell; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2010-04       Impact factor: 2.803

3.  The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009).

Authors:  David J Farrell; Mariana Castanheira; Helio S Sader; Ronald N Jones
Journal:  J Infect       Date:  2010-09-08       Impact factor: 6.072

4.  A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea.

Authors:  Edward W Hook; Matthew Golden; Brian D Jamieson; Paula B Dixon; Hanne S Harbison; Sylvan Lowens; Prabhavathi Fernandes
Journal:  Clin Infect Dis       Date:  2015-06-18       Impact factor: 9.079

5.  In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?

Authors:  Daniel Golparian; Prabhavathi Fernandes; Makoto Ohnishi; Jörgen S Jensen; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

Review 6.  Global resistance of Neisseria gonorrhoeae: when theory becomes reality.

Authors:  David A Lewis
Journal:  Curr Opin Infect Dis       Date:  2014-02       Impact factor: 4.915

  6 in total
  2 in total

1.  In Vitro and In Vivo Activities of TP0480066, a Novel Topoisomerase Inhibitor, against Neisseria gonorrhoeae.

Authors:  Aiko Masuko; Iichiro Takata; Kiyoko Fujita; Hirotoshi Okumura; Fumihito Ushiyama; Hideaki Amada; Hiroyuki Sugiyama
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Evaluation of apramycin against spectinomycin-resistant and -susceptible strains of Neisseria gonorrhoeae.

Authors:  Stefan Riedel; Divya Vijayakumar; Gretchen Berg; Anthony D Kang; Kenneth P Smith; James E Kirby
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.